MidaSol non-injectable Insulin addresses the unmet need of diabetic patients who are dependent on insulin injections by providing a more convenient, non invasive, treatment option.
The companies are conducting a Phase I clinical study of their most advanced candidate which utilizes insulin-passivated gold glyconanoparticles (MidaForm insulin) formulated into PharmFilm for buccal delivery.
Results of the Phase I study are expected in the first half of 2012.
MonoSol president and CEO Mark Schobel said the MidaSol launch is designed to accelerate the commercialization of the innovative insulin, GLP-1 and insulin/GLP-1 products for the treatment of diabetes.